From: Reliability of dynamic susceptibility contrast perfusion metrics in pre- and post-treatment glioma
Group | Total (n = 40) | Pre-treatment group (n = 20) | Post-treatment group (n = 20) |
---|---|---|---|
Mean age at imaging ± standard deviation (years) | 61 ± 13.6 | 61 ± 13.2 | 60 ± 13.4 |
Gender (n, %) | |||
F | n = 24, 60% | n = 13, 65% | n = 11, 55% |
M | n = 16,40% | n = 7, 35% | n = 9, 45% |
Histologically confirmed diagnosis (n, %) | WHO II: 8, 20% WHO III: 2, 5% WHO IV: 30, 75% | WHO II: 4, 20% WHO III: 1, 5% WHO IV: 15, 75% | WHO II: 4, 20% WHO III: 1, 5% WHO IV: 15, 75% |